Suppr超能文献

肾移植肾切除术后的抗人白细胞抗原致敏:术后一年的变化及静脉注射免疫球蛋白的有益作用

Anti-HLA sensitization after kidney allograft nephrectomy: changes one year post-surgery and beneficial effect of intravenous immunoglobulin.

作者信息

Matignon Marie, Leibler Claire, Moranne Olivier, Salomon Laurent, Charron Dominique, Lang Philippe, Jacquelinet Christian, Suberbielle Caroline, Grimbert Philippe

机构信息

Nephrology and Renal Transplantation and CIC-BT 504 Department, Henri Mondor Hospital, APHP, Créteil, France.

INSERM U955, Paris Est University, Créteil, France.

出版信息

Clin Transplant. 2016 Jun;30(6):731-40. doi: 10.1111/ctr.12743. Epub 2016 May 2.

Abstract

The analysis of anti-HLA sensitization at the time of and following allograft nephrectomy may help clinicians to define better both the indications for nephrectomy and preventive therapeutic strategies. We carried out a retrospective analysis of anti-HLA antibodies in 63 clinically indicated nephrectomies (baseline and three and 12 months after) according to the time elapsed since transplantation (six months) and clinical background. An intervention study included 10 patients without donor-specific antibodies (DSA) at the time of nephrectomy treated with high-dose intravenous immunoglobulin (IVIG) (1.5 g/kg). Early nephrectomies were performed in 15 patients (24%). Among the late nephrectomies, 14 patients (22%) were asymptomatic and 34 (54%) had graft intolerance syndrome (GIS). At baseline, anti-HLA sensitization was significantly lower in the early and late asymptomatic groups than in the GIS group, but increased considerably within the three months following surgery. In the group of 10 patients treated with IVIG, only the number of class I non-DSA increased in the three months after surgery, whereas in the control group (N = 13), all anti-HLA variables increased significantly. All patients undergoing a clinically indicated allograft nephrectomy become highly sensitized within the 12 months after surgery. In patients without DSA before nephrectomy, high doses of IVIG may prevent anti-HLA sensitization.

摘要

对同种异体肾移植肾切除术时及术后的抗人白细胞抗原(HLA)致敏情况进行分析,可能有助于临床医生更好地明确肾切除术的指征以及预防性治疗策略。我们根据移植后的时间(6个月)和临床背景,对63例临床指征性肾切除术(基线、术后3个月和12个月)患者的抗HLA抗体进行了回顾性分析。一项干预性研究纳入了10例肾切除时无供者特异性抗体(DSA)的患者,给予大剂量静脉注射免疫球蛋白(IVIG)(1.5 g/kg)治疗。15例患者(24%)进行了早期肾切除术。在晚期肾切除术中,14例患者(22%)无症状,34例(54%)患有移植耐受不良综合征(GIS)。基线时,早期和晚期无症状组的抗HLA致敏率显著低于GIS组,但术后3个月内显著升高。在接受IVIG治疗的10例患者组中,术后3个月仅I类非DSA数量增加,而在对照组(N = 13)中,所有抗HLA变量均显著增加。所有接受临床指征性同种异体肾移植肾切除术的患者在术后12个月内均会出现高度致敏。对于肾切除术前无DSA的患者,大剂量IVIG可能预防抗HLA致敏。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验